ArticleAME case reports2025
Heterogeneity and co-occurrence of resistance mechanisms in EGFR-TKI-induced NSCLC to SCLC transformation: a case report.
Article in AME case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transformation into small-cell lung carcinoma (SCLC) is a common acquired resistance mechanism to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Re-tumor biopsy is crucial for identifying the definite tumor resistance mechanism. However, multiple mechanisms may occur simultaneously during TKI treatment. A single biopsy specimen is insufficient to accurately represent all resistance mechanisms at progressive sites. Case Description: In this case, we present a 58-year-old male with metastatic pulmonary adenocarcinoma (ADC) who had an EGFR exon 19 mutation and received first-line gefitinib and second-line osimertinib. Biopsy results from different progressive sites confirmed the presence of SCLC in pleural metastatic specimens, while the primary tumor had the EGFR exon 19 mutation and mutations ofPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) andv-Ki-ras2-Kirsten rat sarcoma viral oncogene homolog (KRAS). We utilized an effective combination therapy of permanent radioactive iodine-125 seed implantation (PRISI) as local consolidative therapy (LCT), along with the standard carboplatin-etoposide regimen for SCLC and continued osimertinib. Extracranial tumors were successfully controlled. The patient succumbed to intracranial disease progression without radiotherapy, with an overall survival (OS) of 15 months after SCLC transformation. Conclusions: Confirming SCLC transformation from a single site alone through biopsy may not provide a comprehensive understanding of the resistance mechanisms underlying progression at all sites. This highlights the significance of combined treatment strategies, particularly with LCT, for heterogeneous tumors in SCLC transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.